<DOC>
	<DOCNO>NCT01520740</DOCNO>
	<brief_summary>This study evaluate effect baseline collateral ventilation status outcomes follow treatment AeriSeal System patient advance upper-lobe predominant heterogenous emphysema .</brief_summary>
	<brief_title>Collateral Ventilation Effects Response AeriSeal System Treatment Upper Lobe Predominant Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Willing able provide inform consent participate study Age &gt; = 40 year time screen Advanced upper lobe predominant emphysema CT scan Two ( 2 ) subsegments appropriate treatment base upon CT scan 2 different upper lobe segment lung ( total 4 available subsegments ) MRCD questionnaire score 2 great screening Failure medical therapy provide relief symptom Spirometry 15 minute administration bronchodilator ( BOTH ) : FEV1 &lt; 50 % predict FEV1/FVC ratio &lt; 70 % Lung volume plethysmography ( BOTH ) : TLC &gt; 100 % predict RV &gt; 150 % predict DLco &gt; = 20 &lt; = 60 % predict Oxygen saturation ( SpO2 ) &gt; 90 % &lt; = 4 L/min supplemental O2 , rest SixMinute Walk Test distance &gt; = 150 Abstinence smoking least 16 week prior screen Prior lung volume reduction surgery , prior lobectomy pneumonectomy , prior lung transplantation , prior airway stent placement , prior pleurodesis , prior endobronchial lung volume reduction therapy type Requirement ventilator support ( invasive noninvasive ) Three ( 3 ) COPD exacerbation require hospitalization within 1 year Screening visit COPD exacerbation require hospitalization within 8 week Screening visit α1 antitrypsin serum level &lt; 80 mg/dl ( immunodiffusion ) &lt; 11µmol/L ( nephelometry ) Screening visit absence enzyme replacement therapy . Patients document α1 antitrypsin deficiency require replacement therapy exclude study participation . Pulmonary hypertension , define : Echocardiogram estimate peak systolic pressure &gt; 45 mmHg presence tricuspid valve regurgitation state echocardiogram report If echocardiogram show peak systolic pressure &gt; 45 mmHg , right heart catheterization require rule pulmonary hypertension , define peak systolic pressure &gt; 45 mmHg mean pressure &gt; 35 mmHg Clinically significant asthma ( reversible airway obstruction ) bronchiectasis CT scan : Presence follow radiologic abnormality : Pulmonary nodule CT scan great 1.0 cm diameter ( Does apply present 2 year without increase size proven benign biopsy/PET ) Radiologic picture consistent active pulmonary infection , e.g. , unexplained parenchymal infiltrate Significant interstitial lung disease Significant pleural disease Giant bullous disease ( predominant bulla &gt; 10 cm diameter ) Use systemic steroid &gt; 20 mg/day equivalent , immunosuppressive agent , heparin , oral anticoagulant ( e.g. , warfarin , dicumarol ; note : antiplatelet drug include aspirin clopidogrel permit ) investigational medication within 4 week screen Allergy sensitivity medication require safely undergo AeriSeal System treatment Participation investigational study drug , biologic , device currently approve marketing within 30 day prior screen visit Body mass index &lt; 15 kg/m2 &gt; 35 kg/m2 Female patient pregnant breastfeed planning pregnant next year Significant comorbidity carry prohibitive risk associate less 2year expect survival , include follow : HIV/AIDS Active malignancy Stroke TIA within 12 month screen Myocardial infarction within 12 month screen Congestive heart failure within 12 month screen define clinical evidence right leave hear failure leave ventricular ejection fraction &lt; 45 % echocardiogram Any condition Investigator believe would interfere intent study would make participation best interest patient alcoholism , high risk drug abuse noncompliance return followup visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Gold Stage III</keyword>
	<keyword>Gold Stage IV</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Lung Volume Reduction Surgery</keyword>
	<keyword>LVRS</keyword>
	<keyword>Bronchoscopic Lung Volume Reduction</keyword>
	<keyword>BLVR</keyword>
	<keyword>Upper Lobe Predominant</keyword>
	<keyword>ULP</keyword>
	<keyword>Heterogeneous</keyword>
	<keyword>Homogeneous</keyword>
</DOC>